Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Safe, Effective Care for POF.
Modern therapies open doors to renewed ovarian function. Reclaim the dream of biological motherhood.
Free Download: Stem Cell Therapy for Premature Ovarian Failure
Disclaimer:
The information provided by R3 Stem Cell is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and are not guaranteed. The FDA considers stem cell therapy experimental at this point.
Any claims made on this website refer to procedures performed OUTSIDE of the USA. R3 Stem Cell has clinics in Mexico, Philippines, South Africa, Turkey, India, Pakistan.
Please fill out the form below to receive the guide
Every day, R3 Stem Cell receives inquiries worldwide from individuals asking if stem cell therapy can help for Premature Ovarian Failure (POF). Spoiler alert: It can help a lot! In this guide, we’ll go through the basics of how stem cells and exosomes work for POF, the latest research, and what to expect with a regenerative procedure.
Conventional treatments for POF are often not able to regenerate and repair ovarian tissue and follicular activation significantly. For women who desire conception spontaneously or with IVF, failure with conventional treatments is disappointing and entails a significant time factor with it.
Stem cell therapy for POF is turning out to be an excellent opportunity for individuals to achieve functional restoration of the ovaries. Let’s dig in!
Discuss your POF treatment plan today—contact us at (844) GET-STEM.
The ovaries are complex and critical reproductive organs in the female body. Multiple factors can affect the function of ovaries leading to infertility in females. The outside layer of the ovaries contains unique structures known as follicles.
These follicles produce an oocyte (immature egg), which becomes mature into a fertilizable egg by a process known as folliculogenesis. Ovarian follicles include three categories of cells: oocytes, theca and granulosa. Follicle growth and development depend on the follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptors, which are found in the granulosa and theca cells. Folliculogenesis is a well-planned and regulated process. The process involves the development of primordial follicles into primary, preantral, and ultimately antral follicles.
Ovulation happens after this stage. The number of primordial follicles is restricted during a woman’s reproductive life. Females are said to have entered reproductive senescence or menopause when their reserve is depleted. There are around 6 to 7 million germ cells in a female fetus. Approximately 400,000 to 500,000 primordial follicles persist by the time a girl enters adolescence. Approximately 1000 follicles each month are lost after menarche.
Around age 50, there are only around 1000 follicles left after the number of follicles reduces to about 25,000 after age 37, and the rate of follicular loss increases. Thus, throughout a woman’s reproductive life, only about 400 follicles will develop and ovulate, with the large bulk never doing so.
POF affects approximately 1% of women of childbearing age. Although 5–10% of patients may conceive naturally, conventional infertility treatments, including assisted reproductive technology, often prove ineffective for the majority. For infertile patients with POF, oocyte donation or adoption exist, although a prevalent desire persists among them to have biological children. Stem cells, which are characterized by their undifferentiated nature, self-renewal capability, and potential to differentiate into various cell types, have emerged as promising avenues for treating POF. Stem cell therapy can potentially reverse the diminished ovarian endocrine function and restore fertility.
Premature ovarian failure (POF), aka (POI) Primary ovarian insufficiency or early menopause, is a puzzling and complex condition. POF affects one in every 250 women under 35 years and one in every 100 women under 40 years. POF has significant health implications for women.
POF diminishes the likelihood of a natural pregnancy significantly.
Vaginal dryness, discomfort, and itching are the most prevalent urogenital symptoms. Sexual function is further hampered by urogenital atrophy and hypoestrogenism. A decline in bone mineral density (BMD) is a hazard to POF patients. In addition to experiencing psychological anguish, investigations on POF women have found that they have a higher chance of developing neurodegenerative disorders.
Generally, POF women’s life span is decreased due to cardiovascular illness, osteoporosis and sexual dysfunction. Hypergonadotropinism and amenorrhea are also among the main POF characteristics that lead to premenopausal syndrome and female infertility.
Your POF care specialists are available at (844) GET-STEM.
The essential processes in POF are follicle depletion and follicular dysfunction. The quality of the oocytes and follicular pool can be affected by genetic, paracrine, endocrine, mitochondrial dysfunction, and metabolic variables, yet the origin of POF is unknown. A high FSH level is a clear indicator of ovarian failure.
Among the leading causes of POF are Iatrogenic factors, such as pelvic surgery and chemotherapy, environmental factors, such as viral infections, radiation, and toxins, autoimmune diseases with anti-ovarian antibodies causing ovarian damage, and genetic changes, such as point mutation, chromosome imbalances involving the X chromosome or autosomes. Over 50% of POF cases are still idiopathic despite improvements in medicine.
Genetics may directly cause the disease or merely predispose a person to it. Regarding POF, certain elements may be found in around 20–25% of instances. POF is inherited in 4–31% of cases, with an X-chromosome aberration playing a crucial part in the condition.
Conventional treatments for POF include hormone replacement therapy, androgen, counseling, synthesized bioidentical hormones, Dehydroepiandrosterone, donated oocytes, exercise and diet, and stem cell treatment. Hormone replacement therapy (HRT) is the most prevalent POF treatment.
The role of HRT in boosting fertility, on the other hand, is still debatable. Alternative therapies should be used to lessen the symptoms and risks associated with POF, as HRT is regarded as dangerous in women who have a history of ovarian cancer or breast cancer; it also raises the risk of blood clots, cancer, strokes, and other complications.
Egg donation is the last and most hopeful option for most POF women. However, donation of egg supplies is limited, and patients who receive these eggs will not be able to produce biological children of their own. As a result, specialists are on the lookout for more effective and innovative POF treatments. Scientists are turning to alternate therapies, such as stem cell therapy, to treat POF and other kinds of infertility due to adverse effects connected with HRT therapy used to treat POF and different types of infertility.
SC therapy has shown encouraging outcomes thus far, with spontaneous pregnancies occurring in women with a poor ovarian reserve who had bone marrow Stem Cell therapy. Extensive investigations on SCs capable of producing oocytes have been carried out in mice and humans. These findings give a reason for optimism in developing novel POF/POI therapies. By increasing the number of primordial follicles, decreasing granulosa cell (GC) mortality, and restoring ovary sex hormone activity, SCs from diverse sources may aid and support the restoration of ovarian function.
It has been demonstrated in several investigations that these UCMSCs can repair compromised ovarian function by producing cytokines and other factors involved in proliferation and tissue formation. Here is a proposed explanation of the fundamental mechanism of action that stem cells are thought to have (see figure below).
The first clinical studies were conducted on people using MSCs from bone marrow (BM) with iliac crest aspiration for cell collection, stem cell isolation, and invitro culture methods. A stem cell therapy resulting in the live birth of a 2.7 kg female baby by a 45-year-old perimenopausal lady was reported by Gupta et al.
When R3 Stem Cell performs the POF procedure, a transvaginal ultrasound probe guides the cannula into each ovary, where stem cells and exosomes are injected. It’s a safe, effective and well tolerated procedure.
In a 2020 study by Zafardoust et al, autologous human menstrual blood stem cells were injected into the left ovary of women with POI, resulting in natural pregnancies in 4 of 15 women 3 months after transplantation. The control group that underwent routine intracytoplasmic sperm injection did not achieve pregnancy during the same period. Clinical pregnancies were observed in 7 of 15 women in the experimental group, with 5 of 7 successfully giving birth. No significant differences in the AMH levels, mean antral follicle count (AFC), or oocyte number were observed between the two groups. However, the oocyte fertilization rate and embryo number improved in the stem cell group, suggesting paracrine effects rather than oocyte differentiation.
Zhu et al. further compared the efficacy of intraovarian injection of UC-MSCs with intravenous injection, noting faster restoration of ovarian function in the intraovarian injection group, although the long-term restoration was similar in both groups. This was an animal study.
Reduce neuropathy symptoms with regenerative care—call (844) GET-STEM.
Most human studies on MSC therapy have demonstrated the effectiveness of stem cells in treating POF, with evidence showing that these cells may develop into ovarian follicles and regain ovarian function. The therapeutic action of MSCs is generally regulated by a complex web of biological processes rather than a single component. Following MSC migration to the damaged ovary, paracrine effects control ovarian cell proliferation, induction of apoptosis and autophagy, immunization, fibrosis, and oxidative stress.
The mesenchymal stem cells that are extracted from the human umbilical cord (hUC-MSCs) comprise umbilical cord tissue-derived stem cells, and they retain not only mesenchymal stem cells’ essential characteristics but also have a strong capacity for proliferation and differentiation.
Stem cells and exosomes act in the body through several mechanisms. They do NOT become part of a patient’s DNA, which means they do not engraft into the person’s existing cells.
They act through:
Angiogenesis
provokes formation of new blood vessels.
Reduce inflammation
POF is associated with significant inflammation, and the regenerative biologics reduce it nicely.
Immune system modulation
the stem cells and exosomes modulate the immune system very differently than steroids. Instead of blanketly suppressing the immune system, the regenerative biologics tamp down the harmful processes while amping up the beneficial ones. This includes ramping up production of several helpful growth factors and cytokines, while tamping down harmful ones.
Cellular signaling
the biologics are able to perform “cell to cell” communication. This promotes recipient cells to proliferate their growth factor production, protein production and regenerate tissues that are damaged.
Prevent cell death
most cells have a timed death, where they are only allowed to live a certain length of time. This is called apoptosis. The regenerative biologics allow normally functioning cells (i.e. ovary granulosa cells) to live longer, and spare them from the pre-programmed death.
Preventing scar tissue
Once that scar tissue forms, it becomes nonfunctional. Stem Cells and exosomes are great at preventing scar tissue (antifibrosis).
Stem Cells can also release a huge variety of molecules into the extracellular environment. These molecules, which include extracellular vesicles (exosomes), lipids, free nucleic acids, and soluble proteins, exert crucial roles in repairing damaged tissue. Along with offering stem cells for treatment of POF, R3 Stem Cell includes stem cell exosomes, which are a type of extracellular vesicle participating in extensive cell to cell communication for ovarian tissue repair and regeneration.
The stem cells administered by R3 are not the ones that become a patient’s new follicle. The administered mesenchymal stem cells are not specifically designed to replace damaged and lost follicles, but rather coordinate and enhance an ovarian repair response by one’s own mechanisms.
Non-surgical ovarian repair. Call (844) GET-STEM for procedure info.
Where do the stem cells and exosomes come from?
R3 Stem Cell’s regenerative biologics originate from umbilical cord tissue that has been donated after a scheduled c-section. No baby (or mother) is harmed during the c-section procedure. The umbilical cord tissue is normally discarded, but if the mother passes screening test then the umbilical cord is immediately sent to the lab.
The lab carefully processes the umbilical cord to generate large amounts of stem cells and exosomes that are of the highest quality possible. The lab team consists of multiple PhD’s working in ISO Certified, cGMP compliant clean rooms to ensure quality assurance that exceeds USA FDA standards. The proprietary production process combines the highest potency, safety and affordability for providers to confidently offer exosome procedures.
Millions of dollars have been invested into the pharmaceutical grade production of the biologics including first rate clean rooms, bioreactors, nano-particle tracking analyzers, cytometers, PCR, tangential flow machines and real time environmental monitoring. The quality assurance testing complies with screening and testing stan¬dards consistent with the American Association of Tissue Banks, cGMP standards, FDA regulations and the highest level of any regulatory agency globally.
Stem Cell Derived Exosomes
R3 Stem Cell’s Centers of Excellence globally include umbilical cord stem cell derived exosomes with umbilical cord stem cells to provide enhanced results. Exosomes are lipid bound vesicles (acellular) produced by cells which contain a plethora of growth factors, cytokines, mRNA and other proteins.
They are exceptionally helpful in cell-to-cell communication, and very effective for reducing inflammation when they become ingested by their recipient cell. They act as shuttles to send nucleic acids and proteins to other cells, in this way, allowing cell-to-cell communication and transporting molecules among both close and distant cells. In general, these released proteins are important regulators of intracellular information.
Exosomes could be the mediators of many stem cell-associated therapeutic activities. Considering they are 100 times smaller than stem cells, they do not have any issues passing through the blood-brain-barrier to reach the brain from the bloodstream.
Explore stem cell therapy for peripheral neuropathy. Call (844) GET-STEM.
Is stem cell therapy safe?
After a decade of performing over 24,000 stem cell procedures worldwide, R3 knows that the regenerative procedures are safe. The quality control employed during the stem cell production is second to none, and the side effects R3 sees are usually mild to moderate and temporary.
They may include itching, dizziness, lightheadedness, low grade fever, chills, headache, nausea. These are typically temporary. If a patient has an allergic reaction to the multivitamin or a preservative, all of R3’s Centers have the medications to resolve it quickly.
One of the questions we get asked a lot is, “Will the stem cells get rejected?” The answer is NO.
MSCs do not express major histocompatibility complex (MHC) antigens of the class II subtype and contain low levels of MHC molecules of the class I subtype. MSCs also lack the co-stimulatory molecules essential for immune detection, including CD40, CD80, and CD86.
Therefore, MSCs generally have low immunogenicity and can avoid immune rejection by the recipient, which serves as the foundation for their successful application without needing to match the donor to the recipient. Scientists call this being“immunologically privileged”.
Another question often asked is“Is there a chance of a tumor forming?” Once again the answer is NO. The mesenchymal stem cells and exosomes used during treatment have never been shown to have tumor forming potentials. In fact, they have been shown to be anti-tumor forming.
Reverse POF symptoms safely. Call (844) GET-STEM for protocols.
Treatment Protocol
For the past decade, R3 has been successfully treating patients with stem cell and exosome therapies with injection, infusion, intranasal, intrathecal and now, intra-ovarian procedures.
For POF, R3’s providers use between 100 million stem cells up to 150 million stem cells (depends on patient weight). In addition, billions of stem cell exosomes and platelet rich plasma therapy (PRP) are included at no cost.
R3 Stem Cell’s POF treatment protocol includes transvaginal ultrasound guidance for accuracy and safety, along with exosomes and platelet rich plasma therapy to increase the effectiveness of the therapy. IV treatment is also part of the protocol. Safety is paramount with the biologics products being rigorously tested prior to use, and expert providers managing each treatment as if you are a family member!
Why does R3 Stem Cell use donor tissue for its stem cells?
Although autologous (your own) stem cells provide significant advantages, allogeneic (donor) stem cells have more advantages. First of all, autologous MSCs need a long time to culture and expand, which limits its application in treatment, while allogeneic stem cells can be obtained and expanded more quickly, thus avoiding the delay of time window. Second, age is a factor that affects the physiological characteristics of MSCs. Studies have shown that stem cells from elderly donors have decreased proliferation and differentiation ability. This means they are less in number and less effective!
Similar to the research mentioned above, R3 Stem Cell’s outcomes for SLE patients have been exceptional! The patient satisfaction rate is 85% year over year. Patients typically see exceptional pain relief, increased range of motion, improved function and less need for traditional medications.
It may take four to six weeks for the results to kick in, although we have had patients symptomatically feel much better within the first couple of weeks. It should be noted, again, that stem cell therapy does not eliminate SLE, and may need to be repeated every one to three years.
Stem cell therapy for POF may be the key step in achieving a successful pregnancy, and we want to make it affordable for as many individuals as possible. Our global volume has allowed us to keep our patient cost as low as possible.
Unfortunately, stem cell clinics in Colombia, China and Panama charge over $20,000 USD for POF treatment. How are individuals supposed to budget for that?? R3 Stem Cell’s fees are less than half that for full treatment, which also includes free exosomes, PRP and a multivitamin infusion!
For the past decade, R3 Stem Cell’s Centers globally have performed over 24,000 regenerative procedures in six countries. Patient satisfaction across all conditions treated is very high, at 85%. However, MSC treatment for POF is a MUCH newer option, so satisfaction percentages haven’t been definitively established. R3 combines safety, effectiveness and affordability for the therapies. Internationally, the Intellicell is used, which is culturing the most active mesenchymal stem cells to create the “smartest” stem cell in the world!
R3 Stem Cell offers free consultations for individuals to discuss whether regenerative therapy is indicated for your POF. Simply call (844) GET-STEM to schedule yours!
References
David Greene, MD, PhD, MBA, Founder/CEO
R3 Stem Cell offers treatments that bring patients hope and options. Hope that surgery can be avoided, and tissue injury can be repaired with patients being able to get back to desired activities.
Founder and CEO David Greene, MD, PhD, MBA writes extensively on regenerative medicine and gives many seminars worldwide on a regular basis. With over forty Centers of Excellence globally, R3 is at the forefront of regenerative therapies.
R3’s Centers have successfully performed over 24,000 regenerative procedures to date. Call today for your free consultation (844) GET-STEM!
No portion of this Document may be reproduced without the Express Written Consent of R3 Stem Cell.
This guide’s education does not constitute medical advice. The USA FDA considers stem cell therapy experimental. Any claims made in the Guide refer to procedures performed outside the USA.
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
R3 Stem Cell is a global leader in regenerative medicine, offering advanced stem cell and exosome therapies through Centers of Excellence in over 45 locations across 7 countries. Our mission is to provide first-rate, customized regenerative treatments, including stem cells, exosomes, PRP, vitamins, and peptides, to help patients achieve a better quality of life. With more than 26,000 procedures performed and an 85% patient satisfaction rate, our experienced, compassionate providers are committed to delivering safe, effective care. All therapies are nonsteroidal, outpatient procedures designed to harness the body’s natural repair mechanisms and support tissue regeneration. Individual results may vary, and only your medical professional can explain all the risks and potential benefits of any therapy based on your unique circumstances.
Stem cell therapy is considered experimental and is regulated by the U.S. Food and Drug Administration (FDA), but it is not FDA-approved. R3 Stem Cell does not offer stem cell therapy as a cure for any medical condition. No statements made on this site have been evaluated or approved by the FDA. This site does not provide medical advice. All content is for informational purposes only and is not a substitute for professional medical consultation, diagnosis, or treatment. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
Disclaimer: The city links above provide general information on stem cell treatment. To find an R3 Stem Cell clinic near you click here
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2025 R3 Stem Cell. All Rights Reserved.
